Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Uber Technologies Inc (UBER) vs GeneDx Holdings Corp (WGS) Price & Performance

Uber Technologies IncTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Uber Technologies Inc vs GeneDx Holdings Corp — how do they compare? Uber Technologies Inc trades at $71.63 (market cap $149.37B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: Uber Technologies Inc is far larger — about 58.3× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Uber Technologies Inc nearer its low. Which is the better fit depends on your goals.

UBERWGS
Market Cap
$149.37B$2.56B
Sector
IndustrialsTechnology
52-Week High
$100.10$167.51
52-Week Low
$65.94$34.51
Enterprise Value
$158.71B$2.60B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Uber Technologies Inc

Uber's stock trades at $71.08, down 6.18% today, amid a bearish technical signal but strong fundamentals. Revenue grew to $52.02B in 2025 with a net income of $10.05B, though Q4 2025 earnings missed expectations. Recent news highlights strategic shifts toward autonomous vehicles, including robotaxi pilots in Spain and Germany, alongside cost-cutting measures like HR layoffs and AI spending caps.

The outlook is mixed: robust revenue growth and a dominant market position support upside, but competitive pressures, regulatory risks, and a projected negative cash flow in 2026 pose challenges. Analyst consensus is strongly bullish with a $102.56 price target, suggesting significant potential if execution aligns with autonomous vehicle initiatives.

GeneDx Holdings Corp

WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.

Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Uber Technologies Inc

Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.

Read more on UBER

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS